ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Healthcare CBOperProf Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCBHHYPOTHETICAL MODEL
Since ’99
+249%
Expense Ratio
0.45%
placeholder
Holdings
93
cap-weighted
Inception
Oct 2020
placeholder
Full Sharpe
0.33
Ann. Return (LS)
6.4%
Ann. Volatility
19.4%
Max Drawdown
-37.1%
Test Sharpe ’19–26
0.42
Test FF5 α (ann.)
9.4%
vs Fama-French 5
Test FF5 α t-stat
1.49
not significant
Monthly turnover
12%
of the long leg, per rebalance
Cumulative return (LS)
249%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.66
what this fund holds
Long leg ann. return
10.6%
buyable, long-only
Long-short Sharpe
0.33
requires shorting
Bottom bucket ann. return
4.3%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

93 of 93 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
43.99%
2MRK
MERCK & CO INCHealthcare$314.90B
12.47%
3GILD
GILEAD SCIENCES INCHealthcare$166.72B
6.60%
4BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
4.91%
5VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
4.88%
6HCA
HCA HEALTHCARE INCHealthcare$82.34B
3.26%
7REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
2.81%
8IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
1.77%
9RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
1.57%
10NTRA
NATERA INCHealthcare$38.87B
1.54%
11ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
1.41%
12ONC
BEONE MEDICINES LTDHealthcare$34.68B
1.37%
13DXCM
DEXCOM INCHealthcare$29.58B
1.17%
14ILMN
ILLUMINA INCHealthcare$28.24B
1.12%
15MTD
METTLER TOLEDO INTERNATIONAL INCHealthcare$26.47B
1.05%
16INCY
INCYTE CORPHealthcare$23.42B
0.93%
17UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.90%
18NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.68%
19THC
TENET HEALTHCARE CORPHealthcare$16.79B
0.67%
20EXEL
EXELIXIS INCHealthcare$14.06B
0.56%
21PODD
INSULET CORPHealthcare$11.36B
0.45%
22ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
0.41%
23CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.38%
24HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.37%
25IONS
IONIS PHARMACEUTICALS INCHealthcare$8.99B
0.36%
26IMVT
IMMUNOVANT INCHealthcare$8.27B
0.33%
27MIRM
MIRUM PHARMACEUTICALS INCHealthcare$7.25B
0.29%
28TXG
10X GENOMICS INCHealthcare$5.55B
0.22%
29TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.21%
30KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.19%
31ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.17%
32VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
0.17%
33DOCS
DOXIMITY INCHealthcare$3.94B
0.16%
34ALMS
ALUMIS INCHealthcare$3.65B
0.14%
35NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.14%
36RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.14%
37IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.13%
38RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.11%
39CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.11%
40KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.11%
41NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.10%
42BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.09%
43BHVN
BIOHAVEN LTDHealthcare$2.32B
0.09%
44CDNA
CAREDX INCHealthcare$2.05B
0.08%
45SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.08%
46HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.08%
47VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
0.07%
48SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.07%
49IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
0.07%
50ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.07%
51VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.06%
52NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.06%
53MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.06%
54NVAX
NOVAVAX INCHealthcare$1.35B
0.05%
55XNCR
XENCOR INCHealthcare$1.30B
0.05%
56INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.05%
57MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.05%
58EYPT
EYEPOINT INCHealthcare$1.12B
0.04%
59FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.04%
60VOR
VOR BIOPHARMA INCHealthcare$980M
0.04%
61ANNX
ANNEXON INCHealthcare$950M
0.04%
62AURA
AURA BIOSCIENCES INCHealthcare$723M
0.03%
63PHR
PHREESIA INCHealthcare$662M
0.03%
64FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.02%
65NPCE
NEUROPACE INCHealthcare$548M
0.02%
66ARVN
ARVINAS INCHealthcare$517M
0.02%
67RGNX
REGENXBIO INCHealthcare$511M
0.02%
68NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.02%
69DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.02%
70PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.02%
71CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.02%
72ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.02%
73STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.02%
74UPB
UPSTREAM BIO INCHealthcare$382M
0.02%
75CV
CAPSOVISION INCHealthcare$335M
0.01%
76FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.01%
77QTTB
Q32 BIO INCHealthcare$255M
0.01%
78ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.01%
79GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.01%
80SPOK
SPOK HOLDINGS INCHealthcare$222M
0.01%
81KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.01%
82AGEN
AGENUS INCHealthcare$209M
0.01%
83DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.01%
84ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.01%
85CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.01%
86PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.01%
87VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.01%
88AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.01%
89CUE
CUE BIOPHARMA INCHealthcare$126M
0.00%
90CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.00%
91ACET
ADICET BIO INCHealthcare$76M
0.00%
92ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.00%
93XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $2.52T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

93 classified
Value
Blend
Growth
Large
Mid
Small
19%7
21%10
56%15
<1%5
1%10
<1%5
<1%15
<1%6
<1%8

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 69% toward Growth. +1% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt99% → Large
SmallLarge
Value ↔ growth tilt69% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
2
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    51.9%
    Margin
    -23.1%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    44.0%
    Margin
    -19.0%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.1 (95% CI 0.7-1.2)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
10.1%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.05x
within
parametric
1.01x
within
cornish fisher
0.92x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2016
Before publication (pre-2016)
0.23
Sharpe · 4.0% p.a.
January 1999December 2016 · 216 mo
Since publication
0.49
Sharpe · 11.0% p.a.
January 2017July 2026 · 115 mo
Change in Sharpe+0.26Sharpe strengthened since publication176% stronger in annual return

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
85%
22 of 26 3-year windows made money
Worst window
-0.62
Sharpe, January 2002 – December 2004
January 1999July 2026
Median Sharpe
0.40
Dispersion
0.43
Best window
1.16

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.44.0%-16.3%
3 yearsp.a.19.3%0.9%
5 yearsp.a.12.2%10.8%
10 yearsp.a.12.0%8.6%
Since inceptionp.a.9.8%4.6%
Calendar years
YearLong legLong-short
20267 mo14.4%-8.5%
202523.8%-23.2%
202411.0%23.4%
20238.5%3.3%
20227.2%59.3%
20219.0%34.5%
202017.7%-1.1%
201921.9%-8.5%
20183.7%15.3%
201715.1%12.3%
2016-14.6%4.8%
20159.6%6.4%
201434.0%10.8%
201349.3%-0.2%
201222.2%6.0%
201122.0%26.8%
20104.7%-14.6%
200914.7%-14.2%
2008-5.9%40.4%
20070.1%-18.9%
20065.6%1.8%
20059.4%18.6%
20043.7%-9.9%
200310.1%-19.9%
2002-21.6%2.9%
2001-14.3%2.1%
200042.2%0.3%
1999-3.6%22.2%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCBH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-10-12 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$2.52T

Methodology

The Foundry Healthcare CBOperProf Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a CBOperProf signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.